The Center for Biosimilars® recaps the top stories for the week of September 30, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 30, 2019.
Number 5: A new report from the House Ways and Means Committee finds that Americans pay nearly 4 times more for drugs than do patients in other countries.
Number 4: During the week’s European Society for Medical Oncology Congress 2019, a research team presented findings from a phase 3 trial of Samsung Bioepis' proposed bevacizumab biosimilar.
Number 3: New research suggests that state-level drug price transparency laws are largely ineffective at revealing true transaction prices.
Number 2: A newly introduced item of legislation proposes to eliminate co-payments for patients when they receive biosimilars in Medicare Part B.
Number 1: Pfizer says that it will launch its bevacizumab biosimilar, Zirabev, in the United States on December 31.
Finally, last week, our e-newsletter asked whether you think that biosimilars of rituximab will make treatment more accessible for patients with neurological diseases like multiple sclerosis.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.